American Journal of Epidemiology Advance Access originally published online on July 13, 2005
American Journal of Epidemiology 2005 162(4):318-325; doi:10.1093/aje/kwi203
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ORIGINAL CONTRIBUTIONS |
Statins and Prostate Cancer Risk: A Case-Control Study
1 Oregon Health & Sciences University, Portland, OR
2 Portland Veterans Affairs Medical Center, Portland, OR
Correspondence to Dr. Jackilen Shannon, Oregon Health & Sciences University, 3181 S.W. Sam Jackson Park Road (CSB669), Portland, OR 97239-3098 (e-mail: shannoja{at}ohsu.edu).
Observational studies have shown that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) use may be associated with reduced cancer risk. The purpose of this case-control study was to elucidate the association between statin use and prostate cancer risk. Prostate cancer cases (n = 100), recruited upon referral for prostate biopsy, and frequency age-matched, prostate-specific antigen-normal clinic controls (n = 202) were recruited from the Portland, Oregon, Veterans Affairs Medical Center. Information on any use of statins from May 1997 through August 2004 was obtained from an electronic pharmacy database. Days of use, type of statin, dose, and prescription changes were recorded. Duration and intensity were calculated for each statin type on the basis of days of use and prescribed dose. Thirty-six percent of cases and 49 percent of controls had a record of any statin use. Following adjustment for other potential risk factors, statin use was associated with a significant reduction in prostate cancer risk (odds ratio = 0.38, 95% confidence interval: 0.21, 0.69). Furthermore, in analyses stratified by Gleason score, the inverse association with statin use was maintained only among men with Gleason scores of 
7 (odds ratio = 0.24, 95% confidence interval: 0.11, 0.53). The results of this case-control study suggest that statins may reduce the risk of total prostate cancer and, specifically, more aggressive prostate cancer.
case-control studies; cholesterol; hydroxymethylglutaryl-CoA reductase inhibitors; mevalonic acid; prostate-specific antigen; prostatic neoplasms; veterans
Abbreviations: CI, confidence interval; FPP, farnesylpyrophosphate; GGPP, geranylgeranyl pyrophosphate; NSAID, nonsteroidal antiinflammatory drug; OR, odds ratio; p21, Mr 21,000 protein (p27 defined similarly); PVAMC, Portland Veterans Affairs Medical Center; VA, Veterans Affairs
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  X. Zheng, X.-X. Cui, Z. Gao, Y. Zhao, Y. Lin, W. J. Shih, M.-T. Huang, Y. Liu, A. Rabson, B. Reddy, et al. Atorvastatin and Celecoxib in Combination Inhibits the Progression of Androgen-Dependent LNCaP Xenograft Prostate Tumors to Androgen Independence Cancer Prevention Research, January 1, 2010; 3(1): 114 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Platz, C. Till, P. J. Goodman, H. L. Parnes, W. D. Figg, D. Albanes, M. L. Neuhouser, E. A. Klein, I. M. Thompson Jr., and A. R. Kristal Men with Low Serum Cholesterol Have a Lower Risk of High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial Cancer Epidemiol. Biomarkers Prev., November 1, 2009; 18(11): 2807 - 2813. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A M Tonkin, A Forbes, and S J Haas The evidence on trial: cholesterol lowering and cancer Heart Asia, March 6, 2009; 2009(2): 6 - 10. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Mascitelli, F. Pezzetta, M. R. Goldstein, and R. H. Samson Questioning the Safety of Life-long Statin Therapy in Patients With Peripheral Arterial Disease Vascular and Endovascular Surgery, February 1, 2009; 43(1): 109 - 111. [PDF]
|
|
|
|
 |
|
 R. J. Hamilton, K. C. Goldberg, E. A. Platz, and S. J. Freedland The Influence of Statin Medications on Prostate-specific Antigen Levels J Natl Cancer Inst, November 5, 2008; 100(21): 1511 - 1518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. Samson The Role of Statin Drugs in the Management of the Peripheral Vascular Patient Vascular and Endovascular Surgery, August 1, 2008; 42(4): 352 - 366. [Abstract] [PDF]
|
|
|
|
 |
|
 I. Agalliu, C. A. Salinas, P. D. Hansten, E. A. Ostrander, and J. L. Stanford Statin Use and Risk of Prostate Cancer: Results from a Population-based Epidemiologic Study Am. J. Epidemiol., August 1, 2008; 168(3): 250 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Jayachandran and S. J. Freedland Prevention of Prostate Cancer: What We Know and Where We Are Going American Journal of Men's Health, June 1, 2008; 2(2): 178 - 189. [Abstract] [PDF]
|
|
|
|
|
|
A. Hoque, H. Chen, and X.-c. Xu Statin Induces Apoptosis and Cell Growth Arrest in Prostate Cancer Cells Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 88 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Murtola, T. L.J. Tammela, J. Lahtela, and A. Auvinen Cholesterol-Lowering Drugs and Prostate Cancer Risk: A Population-based Case-Control Study Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2226 - 2232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. D. Flick, L. A. Habel, K. A. Chan, S. K. Van Den Eeden, V. P. Quinn, R. Haque, E. J. Orav, J. D. Seeger, M. C. Sadler, C. P. Quesenberry Jr., et al. Statin Use and Risk of Prostate Cancer in the California Men's Health Study Cohort Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2218 - 2225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Jacobs, C. Rodriguez, E. B. Bain, Y. Wang, M. J. Thun, and E. E. Calle Cholesterol-Lowering Drugs and Advanced Prostate Cancer Incidence in a Large U.S. Cohort Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2213 - 2217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Platz Epidemiologic Musing on Statin Drugs in the Prevention of Advanced Prostate Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2175 - 2180. [Full Text] [PDF]
|
|
|
|
 |
|
 I. Ford, H. Murray, C. J. Packard, J. Shepherd, P. W. Macfarlane, S. M. Cobbe, and the West of Scotland Coronary Prevention Study Gro Long-Term Follow-up of the West of Scotland Coronary Prevention Study N. Engl. J. Med., October 11, 2007; 357(15): 1477 - 1486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zheng, X.-X. Cui, G. E. Avila, M.-T. Huang, Y. Liu, J. Patel, A. N. T. Kong, R. Paulino, W. J. Shih, Y. Lin, et al. Atorvastatin and Celecoxib Inhibit Prostate PC-3 Tumors in Immunodeficient Mice Clin. Cancer Res., September 15, 2007; 13(18): 5480 - 5487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Khurana, H. R. Bejjanki, G. Caldito, and M. W. Owens Statins Reduce the Risk of Lung Cancer in Humans: A Large Case-Control Study of US Veterans Chest, May 1, 2007; 131(5): 1282 - 1288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Setoguchi, R. J. Glynn, J. Avorn, H. Mogun, and S. Schneeweiss Statins and the Risk of Lung, Breast, and Colorectal Cancer in the Elderly Circulation, January 2, 2007; 115(1): 27 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Platz, M. F. Leitzmann, K. Visvanathan, E. B. Rimm, M. J. Stampfer, W. C. Willett, and E. Giovannucci Statin Drugs and Risk of Advanced Prostate Cancer J Natl Cancer Inst, December 20, 2006; 98(24): 1819 - 1825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Landgren, Y. Zhang, S. H. Zahm, P. Inskip, T. Zheng, and D. Baris Risk of Multiple Myeloma following Medication Use and Medical Conditions: A Case-Control Study in Connecticut Women Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2342 - 2347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bonovas, K. Filioussi, N. Tsavaris, and N. M. Sitaras Statins and Cancer Risk: A Literature-Based Meta-Analysis and Meta-Regression Analysis of 35 Randomized Controlled Trials J. Clin. Oncol., October 20, 2006; 24(30): 4808 - 4817. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Gong, M. L. Neuhouser, P. J. Goodman, D. Albanes, C. Chi, A. W. Hsing, S. M. Lippman, E. A. Platz, M. N. Pollak, I. M. Thompson, et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1977 - 1983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al. Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward Clin. Cancer Res., June 15, 2006; 12(12): 3661 - 3697. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Bravi, L. Scotti, C. Bosetti, R. Talamini, E. Negri, M. Montella, S. Franceschi, and C. La Vecchia Self-reported history of hypercholesterolaemia and gallstones and the risk of prostate cancer Ann. Onc., June 1, 2006; 17(6): 1014 - 1017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hindler, C. S. Cleeland, E. Rivera, and C. D. Collard The Role of Statins in Cancer Therapy. Oncologist, January 1, 2006; 11(3): 306 - 315. [Abstract] [Full Text] [PDF]
|
|